This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02460419
Recruitment Status : Completed
First Posted : June 2, 2015
Last Update Posted : October 28, 2022
Sponsor:
Collaborators:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Affiliated Cancer Hospital of Shantou University Medical College
Information provided by (Responsible Party):
XIANG YANQUN, Sun Yat-sen University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This multicenter, randomised, phase 3 study is to evaluate the survival benefit of maintenance capecitabine plus best supportive care versus best supportive care for metastatic nasopharyngeal carcinoma patients after disease controlled with TPC palliative chemotherapy.

Condition or disease Intervention/treatment Phase
Nasopharyngeal Carcinoma Drug: capecitabine Other: Best supportive care (BSC) Phase 3

Detailed Description:
Firstly diagnosed metastatic nasopharyngeal carcinoma patients will receive 4-6 cycles of palliative chemotherapy with taxol,cisplatin and capecitabine. After disease controlled, they will be randomly assigned to maintenance capecitabine plus best supportive care(BSC) or BSC alone. The primary end point is progression-free survival, the secondary end points are overall survival, duration of response, objective response rate, adverse effects and quality of life.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 104 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomised, Phase 3 Study.
Study Start Date : April 2015
Actual Primary Completion Date : May 2020
Actual Study Completion Date : May 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: maintenance capecitabine
maintenance capecitabine plus best supportive care(BSC)
 Drug: capecitabine
capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
Other Name: Xeloda

Other: Best supportive care (BSC)
Best supportive care and following-up every 6-8 weeks
best supportive care
Best supportive care and following-up every 6-8 weeks
 Other: Best supportive care (BSC)
Best supportive care and following-up every 6-8 weeks


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. progression-free survival [ Time Frame: up to 6 years ]
    the time from randomization to the progression of disease


Secondary Outcome Measures :
  1. overall survival [ Time Frame: up to 6 years ]
    the time from randomization to death

  2. duration of response [ Time Frame: up to 6 years ]
    the time from the date of the first cycle of chemotherapy to the progression of disease

  3. objective response rate [ Time Frame: up to 6 years ]
    CR, PR and SD rate

  4. adverse effects [ Time Frame: up to 6 years ]
    chemotherapy side effects

  5. quality of life of the patients during the Maintenance Capecitabine and/or Best Supportive Care [ Time Frame: up to 6 years ]
    evaluate with FACT-H&N every 3 months after randomiztion


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Firstly diagnosed metastatic nasopharyngeal carcinoma patients
  • Disease controlled after 4-6 cycles of palliative chemotherapy with taxol,cisplatin and capecitabine
  • Eastern Cooperative Oncology Group (ECOG) 0-2
  • Life expectation at least 12 weeks
  • No systemic chemotherapy within 6 months, except for induction chemotherapy or concurrent chemotherapy
  • With at least one measurable lesion
  • Enough blood test
  • Signed informed consent

Exclusion Criteria:

  • Sever heart disease
  • HIV infection
  • Sever infection
  • Brain metastasis, except received radical therapy 6 months ago and stable in 4 weeks
  • Allogeneic organ transplantation
  • Malignancy other than nasopharyngeal carcinoma, except:cervical carcinoma in situ, cured basal cell carcinoma,bladder cancer of Ta,Tis or T1, or any cured cancer for at least 3 years
  • Pregnancy or breast feeding
  • Difficulty in swallowing
  • Received other test drugs
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02460419


Locations
Layout table for location information
China, Guangdong
SunYat-senU
Guangzhou, Guangdong, China, 510060
Sponsors and Collaborators
Sun Yat-sen University
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Affiliated Cancer Hospital of Shantou University Medical College
Investigators
Layout table for investigator information
Study Chair: Xiang Guo, MD Sun Yat-sen University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: XIANG YANQUN, MD,PhD, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT02460419    
Other Study ID Numbers: 2015029
First Posted: June 2, 2015    Key Record Dates
Last Update Posted: October 28, 2022
Last Verified: October 2022
Keywords provided by XIANG YANQUN, Sun Yat-sen University:
Nasopharyngeal carcinoma
metastasis
capecitabine
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Nasopharyngeal Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Nasopharyngeal Neoplasms
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
 Nasopharyngeal Diseases
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Capecitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents